v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company has one reportable segment relating to the development of immunotherapies for mKRAS-positive cancers. The Company’s Chief Operating Decision Maker (“CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the condensed consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and the change in fair value of warrants are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the condensed consolidated statements of cash flows. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the CODM and are reported on the condensed consolidated statements of cash flows. All long-lived assets are located in the United States. The following table presents certain financial data for the Company’s reportable segment (in thousands):
Three months ended June 30,Six months ended June 30,
2026202520262025
Clinical trial expenses$1,598 $3,245 $2,779 $7,438 
Employee related research and development expenses2,763 2,326 5,432 4,623 
Chemistry, manufacturing and controls expenses1,229 384 2,965 1,030 
Other research and development expenses1,221 1,316 2,392 2,452 
Contract and grant reimbursements— (265)— (754)
Employee related general and administrative expenses1,887 1,362 3,712 2,449 
Professional fees and other general and administrative expenses1,731 1,723 3,751 3,589 
Other segment items(1)
(2,212)470 (991)943 
Segment net loss$8,217 $10,561 $20,040 $21,770 
(1)Other segment items include interest income, interest expense, and change in the fair value of liability-classified warrants.
June 30,
2026		December 31,
2025
Total segment assets$31,330 $25,862